Ivonescimab for the Treatment of Thymic Cancer
ConditionThymus Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJonsson Comprehensive Cancer Center
About this trial
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Eligibility criteria
Qualifiers
Male or female ≥ 18 years of age and willing and able to provide informed consent
Cytologically or histologically confirmed thymic carcinoma, which is incurable
Received prior systemic therapy for thymic carcinoma, or is ineligible for or refuses other therapies
Measurable disease, as per RECIST 1.1
Disqualifiers
Prior treatment with an immune checkpoint inhibitor targeted PD-1 or PD-L1. Prior treatment with VEGF inhibitor is allowed
Concurrent enrollment in another clinical study, unless enrolled only in the follow-up period or an observational study
Any chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment in the prior 3 weeks or within 5 half-lives of the medication, whichever is shorter. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable
Thoracic radiation of ≥ 30 Gy within 3 months. Other radiation within 3 weeks with the following exceptions: (a) Stereotactic, palliative radiation for bone metastases is acceptable without a washout; (b) Stereotactic brain radiation for asymptomatic brain metastases is acceptable with a 7 day washout
Trial design
Treatments tested in this trial
- Biopsy Procedure
- Biospecimen Collection
- Computed Tomography
- Ivonescimab
- Magnetic Resonance Imaging
- Questionnaire Administration
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Jonsson Comprehensive Cancer Center
Lead sponsor
Summit Therapeutics
Collaborator
Source ClinicalTrials.gov